Leerink Partners cuts Halozyme Therapeutics rating to Market Perform
Leerink Partners lowered its rating on Halozyme Therapeutics shares to Market Perform from Outperform and lifted its price target to $117 from $110, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Analysts at Leerink Partners downgraded Halozyme Therapeutics to Market Perform from Outperform, while raising the price target from $110 to $117, a 6.4% increase. According to TradingView, the new target implies a 12.9% upside from the November 6 close of $103.63.
Across the five most recent analyst notes over the past 30 days, price targets range from $79 to $149. Citizens maintained Market Outperform with a $149 target, Evercore ISI Group kept Outperform at $125, Wells Fargo kept Equal-Weight at $110, JP Morgan kept Neutral at $79, and TD Cowen kept Buy at $130 as of October 13.
why it matters
The move signals that some analysts have turned more cautious on the stock, although their price targets still span a wide range. Rating changes like this reflect one brokerage's view and rarely move the broader market.
tags
instruments
sources
- Leerink Partners downgrades Halozyme Therapeutics to Market Perform from Outperform — TradingView, 7 November 2026 at 00:49 UTC
- Halozyme Therapeutics Cut to Market Perform From Outperform by Leerink Partners — Dow Jones Newswires, 7 November 2026 at 01:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗